Funding for this research was provided by:
Received: 23 June 2021
Accepted: 30 September 2021
First Online: 19 October 2021
: The study and all interview materials received a priori Independent Review Board (IRB) approval from the New England IRB. Patients provided their consent to participate prior to the start of the study.
: Patients or their caregivers provided written consent for deidentified data to be published or presented.
: MT is an employee of Alexion Pharmaceuticals Inc and may own stock/stock options in that company. SK, KH and NS are employees of IQVIA, which received professional service fees from Alexion Pharmaceutical Inc. for conducting the study.